Teal Drones, Tomahawk Robotics partner for 4-ship multi-vehicle system 07:11 RCAT Teal Drones announced that it has significantly enhanced the capabilities of its 4-Ship multi-vehicle system through a partnership with Tomahawk Robotics. "Our partnership with Tomahawk Robotics takes Teal's 4-Ship to a whole new level - allowing the warfighter in the field to simultaneously control the Golden Eagle and other unmanned vehicles, such as rovers and robots on the ground, as well as other unmanned aircraft - all within a single application on a single pane of glass," said Red Cat Holdings CEO Jeff Thompson. "Allowing fighters to coordinate an arsenal of unmanned systems in the air and on the ground gives them a significant advantage in finding and subduing the enemy. This is a game changer.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
The above robot is not redcat but it is eye opening. Imagine sending 100,000 of them crawling up a mountain to take out snipers.
Now imagine a swarm of drones descending on Moscow--
Now imagine a swarm of drones descending on Moscow--
DA Davidson starts Roblox at Buy on uniqueness of platform, metaverse potential 07:43 RBLX
Fortive sees Q4 adjusted EPS 82c-85c, consensus 86c 07:43 FTV Sees Q4 revenue $1.48B-$1.5B, consensus $1.51B. The company said, "For the fourth quarter of 2022, Fortive anticipates revenue of $1.48 billion to $1.50 billion, diluted net earnings per share from continuing operations to be in the range of $0.59 to $0.61 and adjusted diluted net earnings per share from continuing operations to be in the range of $0.82 to $0.85."
Fortive sees Q4 adjusted EPS 82c-85c, consensus 86c 07:43 FTV Sees Q4 revenue $1.48B-$1.5B, consensus $1.51B. The company said, "For the fourth quarter of 2022, Fortive anticipates revenue of $1.48 billion to $1.50 billion, diluted net earnings per share from continuing operations to be in the range of $0.59 to $0.61 and adjusted diluted net earnings per share from continuing operations to be in the range of $0.82 to $0.85."
Travelzoo expects substantially higher revenue and profitability in Q4 07:32 TZOO
Capricor Therapeutics initiated with a Buy at Ladenburg 07:02 CAPR
Permian Resources reinstated with a Buy at Citi 07:02 PR Citi analyst Paul Diamond reinstated coverage of Permian Resources with a Buy rating and $12 price target following the combination of Centennial Resource Development and Colgate Energy Partners.
MAG Silver reports Q3 production 2,617,146 silver ounces and 5,422 gold ounces 06:53 MAG MAG Silver reported Q3 metal production from the Juanicipio Project. As reported to MAG by the project operator Fresnillo, on a 100% basis, 180,807 tonnes of mineralized material from both underground development and initial stopes were processed during the three months ended September 30, at an average head grade of 513 silver grams per tonne. Total Juanicipio production for the quarter, based on provisional estimates before offtake agreement adjustments, totaled 2,617,146 silver ounces and 5,422 gold ounces. MAG expects to release its full financial and operational results on November 14. Mineralized material from Juanicipio continues to be processed through the nearby Saucito and Fresnillo beneficiation plants. Approximately 70% of the tonnes processed in Q3 were processed at the Saucito beneficiation plant which better resembles that of the Juanicipio plant and provides valuable metallurgical information as we look forward to production commencement at Juanicipio. As previously reported to MAG by Fresnillo, power for final commissioning and start of operations should be available by the end of October, and production ramp up will commence in Q4 of this year.
Capricor Therapeutics initiated with a Buy at Ladenburg 07:02 CAPR
Permian Resources reinstated with a Buy at Citi 07:02 PR Citi analyst Paul Diamond reinstated coverage of Permian Resources with a Buy rating and $12 price target following the combination of Centennial Resource Development and Colgate Energy Partners.
MAG Silver reports Q3 production 2,617,146 silver ounces and 5,422 gold ounces 06:53 MAG MAG Silver reported Q3 metal production from the Juanicipio Project. As reported to MAG by the project operator Fresnillo, on a 100% basis, 180,807 tonnes of mineralized material from both underground development and initial stopes were processed during the three months ended September 30, at an average head grade of 513 silver grams per tonne. Total Juanicipio production for the quarter, based on provisional estimates before offtake agreement adjustments, totaled 2,617,146 silver ounces and 5,422 gold ounces. MAG expects to release its full financial and operational results on November 14. Mineralized material from Juanicipio continues to be processed through the nearby Saucito and Fresnillo beneficiation plants. Approximately 70% of the tonnes processed in Q3 were processed at the Saucito beneficiation plant which better resembles that of the Juanicipio plant and provides valuable metallurgical information as we look forward to production commencement at Juanicipio. As previously reported to MAG by Fresnillo, power for final commissioning and start of operations should be available by the end of October, and production ramp up will commence in Q4 of this year.
2nd Stock Of the Day- Helix
Helix Energy upgraded to Buy from Neutral at BTIG 06:11 HLX BTIG analyst Gregory Lewis upgraded Helix Energy to Buy from Neutral with a $10 price target. The analyst cites Brent oil averaging $90 year-to-date and the Brent futures curve trending above $75 through 2024, which has driven offshore spending sharply this year to be on track to rise about 20%, which is the highest level since 2016. Increasing offshore spending has pushed activity higher for most offshore assets with pricing for everything from deepwater rigs dayrates to supply boats, to Helix's well intervention assets pricing, Lewis tells investors in a research note, adding that this is still the "early innings" of the current up-cycle for offshore O&G services.
Helix Energy upgraded to Buy from Neutral at BTIG 06:11 HLX BTIG analyst Gregory Lewis upgraded Helix Energy to Buy from Neutral with a $10 price target. The analyst cites Brent oil averaging $90 year-to-date and the Brent futures curve trending above $75 through 2024, which has driven offshore spending sharply this year to be on track to rise about 20%, which is the highest level since 2016. Increasing offshore spending has pushed activity higher for most offshore assets with pricing for everything from deepwater rigs dayrates to supply boats, to Helix's well intervention assets pricing, Lewis tells investors in a research note, adding that this is still the "early innings" of the current up-cycle for offshore O&G services.
Macau Casinos see gains cut after new COVID infection, Bloomberg reports 06:06 LVS, MGM, WYNN, MLCO Macau's casino stocks have had their gains cut after the city detected its first new COVID infection in two months, hurting optimism that the enclave would start welcoming back tour groups from mainland China, Jinshan Hong of Bloomberg reports. After rising 3.6% Wednesday morning due to a local media news source reporting that Macau had given guidelines to travel agents on resuming tours from mainland China, the stocks closed only 0.3% higher as concerns spread over COVID dampening the reopening bets. Macau rolled out mass testing Wednesday afternoon. Health officials have said the positive patient had recently traveled between Macau and a neighboring city several times and had not moved around the enclave much, so there is a lower risk of local transmission. Macau's adherence to COVID Zero means even one new infection puts reopening efforts at risk. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link
Bunge raises FY22 adjusted EPS view to at least $13.50 from at least $12.00 06:06 BG FY22 consensus $12.71. Bunge said, "We are increasing our full-year 2022 EPS outlook to at least $13.50 to reflect third quarter results and the current environment. In Agribusiness, full-year results are expected to be up from our previous outlook, but remain down from last year due to lower expected performance in Merchandising, which had a particularly strong 2021. In Refined and Specialty Oils, full-year results are expected to be up from our previous outlook and significantly higher than last year. In Milling, full-year results are expected to be similar to our previous outlook and significantly higher than last year. In Corporate and Other, results are expected to be in line with our previous outlook and last year. In Non-Core, full-year results in the sugar and bioenergy joint venture are expected to be down slightly from our previous outlook and below last year. Additionally, the company now estimates the following for 2022: an adjusted annual effective tax rate of 16%; net interest expense of $300 million; capital expenditures of $600 million; and depreciation and amortization of $400 million."
Bunge raises FY22 adjusted EPS view to at least $13.50 from at least $12.00 06:06 BG FY22 consensus $12.71. Bunge said, "We are increasing our full-year 2022 EPS outlook to at least $13.50 to reflect third quarter results and the current environment. In Agribusiness, full-year results are expected to be up from our previous outlook, but remain down from last year due to lower expected performance in Merchandising, which had a particularly strong 2021. In Refined and Specialty Oils, full-year results are expected to be up from our previous outlook and significantly higher than last year. In Milling, full-year results are expected to be similar to our previous outlook and significantly higher than last year. In Corporate and Other, results are expected to be in line with our previous outlook and last year. In Non-Core, full-year results in the sugar and bioenergy joint venture are expected to be down slightly from our previous outlook and below last year. Additionally, the company now estimates the following for 2022: an adjusted annual effective tax rate of 16%; net interest expense of $300 million; capital expenditures of $600 million; and depreciation and amortization of $400 million."
Cathie Wood's ARK Investment bought 27K shares of Twilio today 20:04 TWLO Cathie Wood's ARK Investment bought 20.2K shares of Rocket Lab today 20:02 RKLB
Poor Cathie... Down to 20,000 share lots-
Chipotle CEO: There is upside to our growth 18:23 CMG In an interview on CNBC's Mad Money, Brian Niccol said he's "really proud" of Q3 results. The cost environment has been tough for a while and the company has had some wage pressure. As a result, Chipotle has taken some pricing along the way, he noted. The teams are doing an incredible job managing all access points. "We have instituted a focus on going back to the basics," he added.
Poor Cathie... Down to 20,000 share lots-
Chipotle CEO: There is upside to our growth 18:23 CMG In an interview on CNBC's Mad Money, Brian Niccol said he's "really proud" of Q3 results. The cost environment has been tough for a while and the company has had some wage pressure. As a result, Chipotle has taken some pricing along the way, he noted. The teams are doing an incredible job managing all access points. "We have instituted a focus on going back to the basics," he added.
Teradyne reports Q3 EPS $1.15, consensus $1.04 17:03 TER Reports Q3 revenue $827.1M, consensus $800.5M. "We delivered revenue and earnings above the mid-point of our July outlook as some supply line constraints eased through the quarter enabling greater than expected shipments to memory, automotive and industrial semiconductor test customers," said Teradyne CEO Mark Jagiela. "The short-term outlook in semiconductor test remains mixed with automotive and industrial demand relatively strong while muted compute and mobility demand persists. In industrial automation, slowing manufacturing activity and foreign exchange headwinds continue to impact our full year growth outlook."
Morgan Stanley expects strong results from Moderna's phase 2 trial in melanoma 16:55 MRNA, MRK Morgan Stanley analyst Matthew Harrison keeps an Equal Weight rating and $175 price target on Moderna (MRNA) while noting that the company's upcoming phase 2 readout in personalized cancer vaccine study in adjuvant melanoma expected by year-end 2022 is his "catalyst driven idea". Given Merck's (MRK) recent opt-in, he is expecting "strong results", the analyst tells investors in a research note, adding that "upside result" would be at a hazard rate ratio of less than or equal to 0.55 and greater than or equal to 10% 12-month recurrence-free survival benefit.
Chubb reports Q3 core EPS $3.17, consensus $2.51 16:46 CB Evan Greenberg, Chairman and CEO of Chubb Limited, commented: "The broad-based strength of the company globally was clearly evident in the quarter, with core operating income up 15% and per share earnings of $3.17 up 20%. All major areas of our business contributed. We produced simply excellent underwriting results despite an active catastrophe quarter. We had record investment income, which is and will be a growing source of earnings; double-digit P&C premium revenue growth in constant dollars, which was well balanced between commercial and consumer lines; and life insurance premiums that more than doubled with the closing of our acquisition of Cigna's business in Asia. P&C underwriting income of $710 million was up 15% and led to a combined ratio of 93.1%, which included pre-tax catastrophe losses of $1.2 billion, with $975 million from Hurricane Ian. For the year, record underwriting income of $3.4 billion was up more than 40% or over $1 billion, with an 87.5% combined ratio, an improvement of nearly three points over prior. We continued to capitalize on rising interest rates, deploying cash at an average reinvestment rate of 5.8% versus a portfolio yield of 3.4%. Adjusted net investment income was a record $1.1 billion, up over 12% and topping $1 billion for the first time. Consolidated net premiums written, which include P&C and life insurance, grew over 17% in constant dollars. We are a global company and published growth was impacted by the strength of the dollar, which is at a 20-year high. P&C grew 11%, with commercial lines up 11.5% and consumer lines up 9.5% in constant dollars. Life premiums grew 117% with the consolidation of Cigna's business in Asia. Commercial P&C pricing remained strong and continued to exceed our loss costs. We are focused on inflation and staying on top of it in terms of both pricing and reserving. Commercial pricing, which includes rate and exposure, increased 8.5% in North America and about 11% in our international operations in constant dollars. While we are operating in a challenging economic and geopolitical environment, we are optimistic about our prospects given the strengths and momentum of our businesses. With the combination of growth and underwriting margins in our P&C businesses; our growth in investment income; and the future revenue and earnings contributions from our life insurance businesses in Asia, we expect EPS to continue to grow at a healthy rate into the future."
Morgan Stanley expects strong results from Moderna's phase 2 trial in melanoma 16:55 MRNA, MRK Morgan Stanley analyst Matthew Harrison keeps an Equal Weight rating and $175 price target on Moderna (MRNA) while noting that the company's upcoming phase 2 readout in personalized cancer vaccine study in adjuvant melanoma expected by year-end 2022 is his "catalyst driven idea". Given Merck's (MRK) recent opt-in, he is expecting "strong results", the analyst tells investors in a research note, adding that "upside result" would be at a hazard rate ratio of less than or equal to 0.55 and greater than or equal to 10% 12-month recurrence-free survival benefit.
Chubb reports Q3 core EPS $3.17, consensus $2.51 16:46 CB Evan Greenberg, Chairman and CEO of Chubb Limited, commented: "The broad-based strength of the company globally was clearly evident in the quarter, with core operating income up 15% and per share earnings of $3.17 up 20%. All major areas of our business contributed. We produced simply excellent underwriting results despite an active catastrophe quarter. We had record investment income, which is and will be a growing source of earnings; double-digit P&C premium revenue growth in constant dollars, which was well balanced between commercial and consumer lines; and life insurance premiums that more than doubled with the closing of our acquisition of Cigna's business in Asia. P&C underwriting income of $710 million was up 15% and led to a combined ratio of 93.1%, which included pre-tax catastrophe losses of $1.2 billion, with $975 million from Hurricane Ian. For the year, record underwriting income of $3.4 billion was up more than 40% or over $1 billion, with an 87.5% combined ratio, an improvement of nearly three points over prior. We continued to capitalize on rising interest rates, deploying cash at an average reinvestment rate of 5.8% versus a portfolio yield of 3.4%. Adjusted net investment income was a record $1.1 billion, up over 12% and topping $1 billion for the first time. Consolidated net premiums written, which include P&C and life insurance, grew over 17% in constant dollars. We are a global company and published growth was impacted by the strength of the dollar, which is at a 20-year high. P&C grew 11%, with commercial lines up 11.5% and consumer lines up 9.5% in constant dollars. Life premiums grew 117% with the consolidation of Cigna's business in Asia. Commercial P&C pricing remained strong and continued to exceed our loss costs. We are focused on inflation and staying on top of it in terms of both pricing and reserving. Commercial pricing, which includes rate and exposure, increased 8.5% in North America and about 11% in our international operations in constant dollars. While we are operating in a challenging economic and geopolitical environment, we are optimistic about our prospects given the strengths and momentum of our businesses. With the combination of growth and underwriting margins in our P&C businesses; our growth in investment income; and the future revenue and earnings contributions from our life insurance businesses in Asia, we expect EPS to continue to grow at a healthy rate into the future."
Biohaven Pharmaceutical announces advancements in MoDE platform technology 16:37 BHVN Biohaven announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases. In 2021, Biohaven entered into a worldwide, exclusive license agreement to develop and commercialize the MoDE platform based on ground-breaking research conducted in the laboratory of Professor David Spiegel at Yale University. Under the license agreement, Biohaven acquired exclusive, worldwide rights to Yale's intellectual property directed to its MoDE technology, which pertains to the clearance of disease-causing proteins and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules. Through the novel approach, Professor Spiegel demonstrated the modularity of the MoDE technology by synthesizing bifunctional molecules that induce the degradation of both antibody and pro-inflammatory cytokine proteins.
Chipotle reports Q3 adjusted EPS $9.51, consensus $9.21 16:10 CMG Reports Q3 revenue $2.2B, consensus $2.23B. Comparable restaurant sales increased 7.6%.
F5 Networks sees FY23 revenue growth 9%-11%, consensus $2.9B 16:09 FFIV "Over the next year, our business is likely to benefit from tailwinds to our systems business as a result of improving component availability and to bear some weight from macroeconomic headwinds. In the balance, we expect to deliver fiscal year 2023 revenue growth of 9% to 11%," continued Locoh-Donou. "We also expect the combination of revenue growth and operating leverage will enable us to deliver non-GAAP earnings growth in the low-to-mid teens in fiscal year 2023." EPS consensus for FY23 is $11.48.
F5 Networks sees Q1 adjusted EPS $2.25-$2.37, consensus $2.58 16:09 FFIV Sees Q1 revenue $690M-$710M, consensus $694.62M.
Chipotle reports Q3 adjusted EPS $9.51, consensus $9.21 16:10 CMG Reports Q3 revenue $2.2B, consensus $2.23B. Comparable restaurant sales increased 7.6%.
F5 Networks sees FY23 revenue growth 9%-11%, consensus $2.9B 16:09 FFIV "Over the next year, our business is likely to benefit from tailwinds to our systems business as a result of improving component availability and to bear some weight from macroeconomic headwinds. In the balance, we expect to deliver fiscal year 2023 revenue growth of 9% to 11%," continued Locoh-Donou. "We also expect the combination of revenue growth and operating leverage will enable us to deliver non-GAAP earnings growth in the low-to-mid teens in fiscal year 2023." EPS consensus for FY23 is $11.48.
F5 Networks sees Q1 adjusted EPS $2.25-$2.37, consensus $2.58 16:09 FFIV Sees Q1 revenue $690M-$710M, consensus $694.62M.
Mike Wilson Morgan Stanley is on Bloomberg right now-
He's ranked just ahead of me.
He's ranked just ahead of me.